Specialty pharmaceuticals—hospital acute care and gastroenterology
Strategic Profile
The company's branded product portfolio includes Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia, serving hospital acute care, gastroenterology, and oncology segments. Cumberland is advancing Phase II studies of ifetroban in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis.
Cyborg Score Rationale
Cumberland shows modest near-term fundamentals with Q1 2026 revenues of $9.1 million and a strategic $100 million exit agreement that unlocks shareholder value. However, post-transaction the company will be a development-stage biotech with pipeline risk concentrated on ifetroban's Phase II programs.
Top Insights
(April 2026) Announced $100 million strategic transaction with Apotex to divest branded U.S. pharmaceutical portfolio while retaining development programs and controlling interest in Cumberland Emerging Technologies
(May 2026) Q1 2026 net revenues of $9.1 million with operating expenses of $12.3 million; net loss of $3.3 million reflects transition costs
(2025) Achieved 18% revenue growth, expanded Vibativ into China, launched Talicia, and received breakthrough clinical results for ifetroban with FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations
(April 2026) Caldolor received FDA approval for expanded indication to include management of postoperative pain, extending non-opioid pain relief options
Named Competitors
Vibativ — IV antibiotic for hospital-acquired infections
Caldolor — Injectable ibuprofen for pain and fever management
Talicia — H. pylori infection treatment with omeprazole base
Ifetroban — Development-stage candidate for rare/orphan fibrotic and immune diseases
Recent Developments
(April 2026) Strategic transaction announced to sell branded U.S. portfolio to Apotex for $100 million, positioning company as development-stage biotech
(May 2026) Q1 2026 earnings: $9.1 million net revenue, $3.3 million net loss, $71 million in total assets
(April 2026) Caldolor approved for expanded indication in postoperative pain management
(2025) Talicia launched, Vibativ approved in China, ifetroban achieved breakthrough results in Phase II studies
Open the full interactive Cumberland Pharmaceuticals Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.